Deals Shaping The Medical Industry, December 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.
You may also be interested in...
Developers of medicines that benefit from the European Medicines Agency’s priority medicines scheme can expect to be eligible for accelerated assessment when they eventually file for approval. But there have been no new entries to the scheme for two months now.
Nine $1bn+ alliances were penned in October. Topping the list was a potential $22bn deal between Daiichi Sankyo and Merck for the global development and commercialization of Daiichi’s DXd antibody drug conjugate candidates patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan.
During Q3, biopharma merger and acquisition deal value reached $13.6bn and drew in $36.5bn in potential deal value from alliances. Device company M&A values reached $4.3bn, while in vitro diagnostics and research tools players’ M&A activity totaled $5.8bn.